WILMINGTON, Mass., May 7, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won a competitive bid for 14 of its next-generation explosives trace detectors (ETDs) including its QS-H150 handheld unit and QS-B220 system to Minsk National Airport in Belarus. Minsk National Airport, the largest airport in Belarus, can accommodate nearly 3.6 million passengers a year. The airport is currently expanding its infrastructure and security systems ahead of the 2014 Men's World Ice Hockey Championships, which Belarus will host from May 9th through 25th 2014.
"We are proud to announce that Minsk National Airport will be added to our growing list of international airports that are implementing our legacy and next-generation ETDs. The QS-H150 and QS-B220 were selected by our new customer over a larger competitors' ETDs due to our systems' superior performance, lower total cost of ownership, and non-radioactive source," stated Implant Sciences' General Manager of Russia and CIS Countries, Ms. Natalya Hall.
Minsk National Airport's Director General Deputy for Aviation Security and Regime, Alexander Apet commented, "In evaluating IMSC equipment, we saw the clear differences and advantages that the QS-B220 and QS-H150 offered over the competing systems we were using at the time. As we expand our airport's facilities and security infrastructure, it is critical that we implement systems that use the latest technological advancements. Implant Sciences' ETDs met and exceeded those expectations and requirements."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company's QS-B220 has received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation